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This review is the fruit of multidisciplinary discussions concerning the continuous
administration of b-lactams, with a special focus on cefepime. Pooling of the analyses
and viewpoints of all members of the group, based on a review of the literature on this
subject, has made it possible to test the hypothesis concerning the applicability of this
method of administering cefepime. Cefepime is a cephalosporin for injection which
exhibits a broader spectrum of activity than that of older, third-generation cephalospor-
ins for injection (cefotaxime, ceftriaxone, ceftazidime). The specific activity of cefepime is
based on its more rapid penetration (probably due to its zwitterionic structure, this
molecule being both positively and negatively charged) through the outer membrane of
Gram-negative bacteria, its greater affinity for penicillin-binding proteins, its weak
affinity for b-lactamases, and its stability versus certain b-lactamases, particularly
derepressed cephalosporinases. The stability of cefepime in various solutions intended
for parenteral administration has been studied, and the results obtained demonstrated
the good compatibility of cefepime with these different solutions. These results thus
permit the administration of cefepime in a continuous infusion over a 24-h period, using
two consecutive syringes.
Keywords b-lactamas, cefepime, cephalosporins, continuous infusion, dosage regimen
Accepted 28 July 2002
Clin Microbiol Infect 2003; 9: 339–348
I N V I T R O A N D E X P E R I M E N T A L
R A T I O N A L E : T H E S T A T E O F
T H E A R T
Pharmacokinetic/pharmacodynamic data
The concept of continuous infusion is based on
knowledge of antibiotic pharmacodynamics. When
aminoglycosides and fluoroquinolones are con-
sidered as concentration-dependent antibiotics,
b-lactam antibiotics exhibit time-dependent bac-
tericidal activity. Therefore, the goal of therapy is
to maintain serum drug concentrations above the
minimum inhibitory concentration (T > MIC) for
the relevant pathogen over most of the dosing
interval [1,2]. Consequently, for therapeutic pur-
poses, it seems justified to update the data in favor
of continuous infusion with b-lactam antibiotics, in
particular with cefepime, considering its activity
mechanism and spectrum.
As early as 1946, Jawetz [3] observed that main-
taining ‘detectable’ blood concentrations of peni-
cillin was an essential element in therapeutic
success; to meet this need, he therefore thought
it desirable to recommend repeated administra-
tions at short intervals or the use of continuous
infusion, without, however, being able to confirm
that this approach was essential, whatever the
clinical situation. Nearly 40 years later, research
teams working with the aid of various animal
models of infection were able to demonstrate
[2,4] that the pharmacodynamic parameter most
predictive of the therapeutic success of b-lactams,
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and particularly cephalosporins, was T > MIC.
Different studies showed that in vivo bacteriostatic
activity was usually attained if the serum concen-
tration of the antibiotic remained higher than the
MIC for a period equal to 30–40% of the interval of
administration, this being independent of the site
of infection (thigh, lung, peritoneum). In a given
model of infection (same animal, site of infection
and bacterial strain), this percentage of time was
smaller for penicillins and carbapenems than for
cephalosporins; this corresponds to differences in
the bactericidal rate observed with these com-
pounds, since carbapenems act more rapidly
and cephalosporins act more slowly. However,
in cases of infections caused by Gram-positive
cocci, particular species (enterobacteria) or specific
strains (Pseudomonas aeruginosa), it appears that a
much more sustained rate of administration, and
thus a longer T > MIC, are essential for therapeu-
tic success. From in vitro data and animal studies,
the minimal desired concentration at steady state
(CSS) for maximization of the bactericidal activity
seems to be 4  MIC [5–8]. This concentration is
not reached for the total dosing interval with the
conventional dosage of cefepime, ceftazidime or
imipenem, as demonstrated by Navas et al. in most
febrile, neutropenic patients [9].
An experimental model [10] was used to deter-
mine the pharmacokinetics of cefepime in the rat
during multiple organ function failure. The pul-
monary concentrations were significantly reduced
by comparison with the healthy control animals,
despite similar plasma concentrations. This indi-
cates that the use of a standard dosage, aimed at
achieving the recommended plasma concentra-
tions, may result in insufficient tissue levels.
The tissue penetration of cephalosporins admi-
nistered in a continuous infusion was studied with
an experimental model of fibrin clots in the rabbit.
The injection of a high dose of cefuroxime or
latamoxef by intravenous bolus resulted in better
penetration than the repeated administration of
small doses, or continuous infusion [11–13]. In
contrast, in the rat, there was no difference
between the penetration of ceftazidime into dif-
ferent tissues in the body following a bolus or
continuous infusion; better penetration of this
antibiotic was observed in pleural exudates after
continuous infusion [14]. In a model of suction
blister fluid in humans, the rate of ceftazidime
penetration following continuous infusion was
lower than that achieved with intermittent infu-
sions (84.5% versus 101.5%) [15]. This difference
was less marked with cefepime: 106% with con-
tinuous infusion versus 113% with intermittent
infusion [16]. This decrease in extravascular diffu-
sion is slight, and could probably be prevented by
a loading dose.
Selection of mutants
Any antibiotic therapy is capable of selecting resis-
tant bacteria in a patient or in his environment.
The selection of resistant mutants is the princi-
pal cause of bacteriologic failure when treating an
initially sensitive Gram-negative bacterial infec-
tion with a cephalosporin.
The most frequently incriminated mechanism is
the production of chromosomal cephalosporinase.
In the event of mutation, hyperproduction of this
cephalosporinase is observed (referred to as dere-
pression), which leads to destruction of the anti-
biotic and a marked rise in MIC values. Cephalos-
porins are among those compounds most affected
by this problem, together with aztreonam. Cefpir-
ome, cefepime and, particularly, imipenem are
much more stable, showing a very moderate
increase in MIC when compared with older cepha-
losporins [17].
Resistant mutants are selected by stages; each
stage corresponds to the incidence of a given
mutation and a maximum concentration above
which mutants are no longer seen. It is important
to be aware of this maximum concentration, or
mutation prevention concentration (MPC), because
as long as the concentration of the antibiotic at
the site of infection exceeds this level, the risk of
selecting a resistant mutant is virtually nil [18–21].
Knowledge of the pharmacokinetics of an anti-
biotic, its MIC versus specific bacterial species, its
incidence of mutation and its MPC, enables a valid
prediction of the risk of selecting a resistant mut-
ant. It is thus possible to determine the optimum
dose and most appropriate method of administra-
tion. The time during which the concentration of
the antibiotic is greater than the MIC and less than
the MPC is called the window of selection; the
bigger this window, the higher the MPC/MIC
ratio, and the longer the half-life of the antibiotic.
Numerous studies have considered the selection
of resistant mutants in vitro, either in a liquid
medium or on a solid substrate.
In a comparative study, Fung-Tomc et al. [19]
compared the selective activity of ceftazidime,
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ceftriaxone, cefpirome and cefepime against ten
sensitive strains of Enterobacter cloacae (MIC 0.12–
0.25 mg/L). The median MIC exceeded 8 mg/L
after 1 day with ceftriaxone, 3 days with ceftazi-
dime, 4 days with cefpirome, and 6 days with
cefepime. Atleast four mechanisms of resistance
were obtained as a function of the antibiotic
employed; the principal mechanisms included
the isolated hyperproduction of chromosomal
cephalosporinase, and a reduction in the porin
Omp-39 of the outer membrane. In most of the
clones, these two mechanisms of resistance were
found in association.
In the case of P. aeruginosa, although cefepime
has an activity which is usually weaker than or
equal to that of ceftazidime, Gradelski et al. [18]
observed a more rapid increase in the geometric
mean of cefepime MIC values until day 4, in
comparison with ceftazidime. However, by day
7, the means reached 8.7 mg/L for cefepime ver-
sus 45 mg/L for ceftazidime. In an unpublished
study performed on a solid substrate, Kitzis et al.
compared ceftazidime and cefepime in five strains
of P. aeruginosa. Versus a fully sensitive strain
(MIC for cefepime: 2 mg/L), an incidence of
between 107 and 109 of resistant mutants was
obtained in 24 h, with an MIC not exceeding
32 mg/L for cefepime and reaching 128 mg/L
for ceftazidime and piperacillin.
The risk of selecting a strain with high-level
resistance thus appears from several studies to
be much lower with cefepime than with ceftazi-
dime or cefotaxime [19–22]. A few epidemiologic
studies have also demonstrated that the first-line
use of cefepime for the treatment of nosocomial
infections appears to be associated with a reduc-
tion in the percentage of Enterobacter or Citrobacter
strains resistant to both ceftazidime and cefepime
[23–27]. However, the risk of selecting resistant
mutants is not absent, particularly when the
microorganism is already endowed with a resis-
tance mechanism, and more generally with P.
aeruginosa [28–32]. Under these conditions, the
MIC values attained may rapidly exceed the cap-
abilities of therapy.
Analysis of all the in vitro data concerning the
selection of resistant mutants strongly suggests
that continuous infusions of cefepime should be
used as a therapeutic schedule. Indeed, main-
taining the currently recommended method of
administration (1 or 2 g every 12 or 8 h) leads to
the presence, for at least 6 h after each injection, of
serum levels between the MIC of a sensitive strain
(0.03–0.25 mg/L) and the MPC; this window of
selection thus implies a risk of selecting a resistant
mutant. In contrast, the administration of cefepime
in a continuous infusion reduces the window of
selection to 6 h, and this only during the first and
last administrations of the antibiotic.
In addition, it would be very simple to eliminate
the few resistant mutants present in the entire
bacterial population from the start, by administer-
ing a loading dose of cefepime. A similar effect
could be obtained through the simultaneous use of
an antibiotic against which no cross-resistance has
been observed: this is the case for aminoglyco-
sides, but not for fluoroquinolones [33,34].
C L I N I C A L D A T A
Clinical studies aimed at demonstrating the super-
ior or even equivalent efficacy of continous infu-
sion versus intermittent infusion, depending on
the mode of administration, are methodologically
difficult to implement. Indeed, it is necessary to
study a very large number of patients to reach a
clear conclusion, which probably explains why
few studies comparing these two methods of
administration can be found in the literature. Only
two randomized, comparative studies have been
published. The study by Bodey et al. [35] com-
pared the efficacies of continuous and intermittent
infusions of cefamandole in a population of neu-
tropenic subjects with infections at different sites.
The second study, by Lagast et al. [36], involved
the use of cefoperazone. In both the infections
treated had been caused by Gram-negative bacilli.
The study conducted by Bodey et al. demonstrated
superior or equivalent clinical efficacy of the
continuous infusion versus intermittent infus-
ion, depending on the subgroup analyzed.
Lagast et al. demonstrated identical efficacies of
continuous and intermittent infusion of cefoper-
azone.
Most published studies are pharmacokinetic
studies in patients in whom the variability of the
pharmacokinetics justifies serum concentration
monitoring.
Three types of clinical situations have been
principally investigated: critically ill patients, or
those suffering from neutropenia or cystic fibrosis.
Findings in the literature have suggested the effi-
cacy of continuous infusions in patients with
neutropenia [37] or those with cystic fibrosis [38]
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who constituted treatment failures under conven-
tional therapy.
Critically ill patients
Most studies target pharmacokinetic data. Criti-
cally ill patients are often infected by multiresis-
tant microorganisms, with high MIC values. In an
in vitro pharmacokinetic model, Mouton and den
Hollander [39] showed that it was necessary to
attain concentrations of at least four to five times
the MIC to inhibit the growth of P. aeruginosa.
Various pharmacokinetic studies have demon-
strated the variability of plasma concentrations,
and notably the residual level (less than five times
the MIC), in critically ill patients, and have con-
cluded that continuous infusion, with or without a
loading dose, made it possible to attain levels
above the required concentrations [40,41]. Very
few clinical studies have been published. In a
preliminary study of cefepime [42], 18 patients
were randomized and then received either 4 g in
a continuous infusion (group 1) or 2 g every 12 h
(group 2), in combination with amikacin, 20 mg/
kg per day, in both groups. There were no sig-
nificant differences in terms of the duration of
ventilation or hospital stay, the cure rate, or the
AUC/MIC ratio of cefepime at 12 and 24 h. In
contrast, T > MIC and the time for which the MIC
values were above five times the MIC (T > 5 MIC)
were significantly higher in the continuous infu-
sion group: 23.84 h  0.2 h versus 20.7 h  3 h,
and 23.61 h  0.6 h versus 16.6 h  6 h, respec-
tively. These results, obtained in a small popula-
tion of patients, demonstrated a pharmacokinetic
advantage in the continuous infusion group.
A study by Nicolau et al. [43] compared the
pharmacokinetics and efficacy of two methods of
administration, continuous and intermittent, of
ceftazidime in the treatment of nosocomial pneu-
monia. These authors demonstrated that there
were no differences between the pharmacokinetic
parameters with the two modes of administration:
total clearance CLT ¼ 142.5  59 mL/min versus
133.2  37 mL/min with intermittent infusion
and continuous infusion, respectively. The phar-
macodynamic results made it possible to demon-
strate that, for the 46 microorganisms isolated
and documented in 27 patients, continuous infu-
sion was a method of administration which
enabled optimization of ceftazidime therapy, in
the knowledge that, whichever patient was con-
sidered, the T > MIC parameter was 100% in the
ceftazidime group with continuous infusion, while
it ranged from 56% to 100% in patients included in
the intermittent ceftazidime group.
Neutropenic patients
Occasional observations have been made which
suggest the efficacy of continuous infusion in the
event of therapeutic failure with intermittent
administration [37,44].
A study by Daenen et al. [45] concerned 12
patients with acute myeloid leukemia who
received 100 mg/kg per day ceftazidime follow-
ing a loading dose of 500 mg. In all patients, the
concentration at the steady state (>20 mg/L) was
attained after between 180 and 240 min. Six
patients responded to empirical treatment, four
of them after 24–72 h of single-drug therapy,
and two after the addition of vancomycin. The
other six patients were considered to be non-
responders; in four cases, the microorganism
was not sensitive to ceftazidime. The authors laid
emphasis upon drug interactions in the infusion
lines that could render the antibiotic ineffective. In
fact, the advantages of continuous infusion, as
suggested by in vitro pharmacodynamic and phar-
macokinetic studies, were not demonstrated in a
large population of patients in whom the two
modes of administration were compared.
Another study [46] enabled comparison of the
population pharmacokinetics of cefepime in onco-
hematologic neutropenic subjects with two modes
of administration (intermittent and continuous
infusion), to measure the interindividual var-
iabilities of cefepime with regard to various phar-
macokinetic parameters, to propose adaptable
controls for cefepime doses based on specific
population estimates in this type of patient, and
to correlate the pharmacokinetic results with effi-
cacy. From a pharmacokinetic point of view, there
was no difference between the two methods of
cefepime administration: total clearance CLT ¼
3.15  1.25 L/h versus 4.58  0.89 L/h, and
apparent distribution volume Vd ¼ 11.40  1.33 L
versus 12.60  0.98 L, respectively, for intermit-
tent infusion and continuous infusion. These
observations confirmed those described for aztreo-
nam, meropenem and ceftazidime in neutropenic
patients, and the pharmacokinetic specificities of
these individuals when compared to those seen in
healthy volunteers.
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Patients with cystic fibrosis
Various studies [47,48] have demonstrated the
pharmacokinetic modifications to b-lactams in cys-
tic fibrosis patients: shortening of the half-life,
increase in clearance, and lower concentration at
the steady state. Superinfection episodes are
caused by P. aeruginosa strains with high MIC
values. With intermittent administration, a period
exists between injections during which concentra-
tions fall below the MIC, which is a factor favoring
the selection of resistant strains. The use of con-
tinuous infusions was proposed as an alternative
in the event of therapeutic failure [38]. Vinks et al.
[49] demonstrated the value of continuous infu-
sions of ceftazidime administered in the home to
17 patients. Ceftazidime was delivered via an
infusion pump at a dose of 100 mg/kg per day
for 3 weeks. The effects of this type of treatment
were studied prospectively over a 2-year period.
Of the 33 cycles of treatment received, 25 could be
analyzed in 12 of the 17 patients. A clinical
improvement was noted in 91% of patients, and
persisted for 4–6 weeks in 70% of them. The num-
ber of cultures positive for P. aeruginosa dimin-
ished significantly during the period of treatment.
The bacterial count had returned to pretreatment
values within 4–6 weeks. Repeated treatments
with ceftazidime as single-drug therapy did not
significantly modify the sensitivity profile. Admi-
nistration at home resulted in reductions in both
direct and indirect costs.
All these studies enable us to conclude that, for
antibiotics with a time-dependent bactericidal
effect and a short elimination half-life, and in
specific populations, continuous infusion consti-
tutes an optimization of the therapeutic schedule.
I N D I V I D U A L O R G E N E R A L I Z E D
D O S A G E : D O E S T H E U S E
O F C O N T I N U O U S I N F U S I O N
E N A B L E T H E O P T I M I Z A T I O N
O F T R E A T M E N T ?
The variables modulating individual pharmacoki-
netic values are the status of the patient (age, body
weight, vital functions, hemodynamic status), the
type and site of infection, and the microorganism
involved. These parameters must be taken into
account when designing antibiotic therapy. They
become determining factors for success in severe
or particularly difficult clinical situations. The
benefits expected of treatment adjusted as closely
as possible to pharmacodynamic principles are
clinical and ecological. They remain to be demon-
strated. It is, however, possible to suggest that the
technical problems of administration can be over-
come. If this is the case, it is necessary to determine
whether continuous administration is better, as
good as or less effective than intermittent admin-
istration, and which is the best way to administer a
b-lactam.
Patient status
The prescription of antibiotic therapy is currently
based on general principles (daily dosage, body
weight, rate of administration). Individualization
of administration has, to date, only concerned
dosage adjustments as a function of weight, diffu-
sion requirements in certain types of difficult tis-
sues (cerebrospinal fluid, bone, vegetations in
infectious endocarditis), or the existence of major
disturbances to the excretory functions or meta-
bolic pathways of the antibiotic (renal impairment,
liver impairment). The clinical situations are
nevertheless particularly heterogeneous. Treat-
ment optimization must ensure the best match
between pharmacokinetic parameters, individual
conditions and the bacteria responsible for the
infection, while complying with pharmacody-
namic and safety requirements.
Plasma pharmacokinetics
Plasma pharmacokinetic studies in patients with
more or less severe infectious diseases who are
receiving b-lactams have shown notable degrees of
interindividual heterogeneity and significant dif-
ferences in comparison with the data observed in
healthy subjects.
In elderly patients with respiratory tract infec-
tions, receiving 1 g intravenously every 12 h,
Kovarik et al. [50] found residual cefepime con-
centrations of 6.0  4.9 mg/L, signifying that
some patients exhibited concentrations in the
order of 1 mg/L. The heterogeneity among the
10 patients was confirmed by half-life values,
which ranged from 1.93 to 6.04 h, and area-
under-the-curve (AUC) values which ranged from
173 to 480 mgh/L.
Benko et al. [51] compared the pharmacokinetic
and pharmacodynamic parameters of ceftazidime
administered via an intermittent or continuous in-
fusion in critically ill patients. With the continuous
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infusion of ceftazidime, pharmacodynamic para-
meters are equivalent to those observed with inter-
mittent dosing, while utilizing one-half of the total
daily dose.
Six patients with acute renal failure due to septic
shock received cefepime at a dose of 2 g twice
daily during continuous venovenous hemodiafil-
tration. Among these patients, Allaouchiche et al.
[52] observed one with a Cmax for cefepime of
11 mg/L, and undetectable concentrations after
6 h of administration.
Tissue pharmacokinetics
The tissue distribution and antibiotic concentra-
tions in critically ill patients are poorly documen-
ted. In elderly subjects, Jonsson and Walder [53]
observed considerable differences in ceftazidime
concentrations in subcutaneous interstitial fluids
during severe infectious disease. Following inter-
mittent intravenous administration, the concentra-
tions in tissue fluids ranged from 1.1 mg/L at the
residual level (range: 0.1–2.3 mg/L) to 7.1 mg/L
(range: 3.4–12.2 mg/L) at the peak. The lowest
values on concentration curves were below
1 mg/L for most of the time. In some patients,
the tissue concentrations were therefore very low.
Interindividual differences in concentrations are
therefore of importance in critical, specific or com-
plicated clinical circumstances. It is necessary to
match dosages with modes of administration in
order to optimize antibiotic therapy in these clin-
ical situations. In this respect, the monitoring of
plasma levels is essential. However, the target
levels are unknown in the case of intermittent
administration, and corrective strategies remain
uncertain. It is clear that the continuous infusion
of b-lactams constitutes a method of administra-
tion which enables adaptability to complex
conditions, with more easily identifiable target
values.
The site of infection
The tissue diffusion of antibiotics depends on
numerous factors related to the compound: phy-
sicochemical and pharmacokinetic characteristics,
and affinity or tropism of the antibiotic with
respect to the tissue involved. The extravascular
diffusion of b-lactam antibiotics does not require
any biochemical transporter. This mechanism of
passive diffusion is found for all tissues in the
body, except for certain protected, or ‘sanctuary’,
sites, as specified by Barza and Cuchural [54]:
central nervous system, eye, and prostate gland.
In principle, it may therefore be anticipated that
the extravascular concentrations will be very simi-
lar to blood concentrations, particularly in the case
of compounds which exhibit low protein binding,
such as cefepime.
The microorganism
It appears that, in most cases, treatment of an
infection with a b-lactam will be optimum if the
plasma concentrations of the antibiotic exceed the
MIC of the incriminated bacteria for a period of at
least 30–40% of the interval of administration.
However, the situation may vary under certain
pathophysiologic circumstances. Indeed, because
of the type of bacteria involved, or the particularly
weakened terrain (neutropenia, critically ill, cystic
fibrosis) in severe infections, it is necessary to
cover considerably more than 50% of the admin-
istration interval [55].
W H A T V A L U E S H O U L D B E
T A R G E T E D F O R T H E C S S / M I C
R A T I O I N T H E E V E N T
O F C O N T I N U O U S I N F U S I O N ?
If we refer to most studies of in vitro bactericidal
kinetics, it appears quite clear that, with b-lactams,
the bactericidal rate reaches a maximum at a con-
centration which is about four to six times the MIC.
This ratio, Css/MIC ¼ 4, has also been found in
models simulating the pharmacokinetics of b-lac-
tams [39], as well as in vivo in a model of rabbit
endocarditis caused by P. aeruginosa and treated
with ceftazidime [56]. With the same model, a
comparative (intermittent versus continuous infu-
sion) study by Robaux et al. confirmed that a Css
around 4–5  MIC was a reasonable therapeutic
target in most clinical settings of severe P. aerugi-
nosa infection, and was at least as efficacious as the
traditional intermittent intravenous infusion [7].
In contrast, strains of P. aeruginosa isolated in
cystic fibrosis patients required ceftazidime con-
centrations which were 10 (non-mucoid strains) to
50 (mucoid strains) times the MIC [8]. Various
other findings seem to demonstrate that the choice
of a target value is not simple. Indeed, earlier dose-
ranging studies in rats with pneumonia caused by
Klebsiella pneumoniae which were treated with con-
tinuous infusion showed that several parameters
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could affect the choice of Css/MIC ratio: severity of
infection, presence of neutropenia, site of infection,
and sensitivity of the bacteria [57,58]. In these
studies, the concentration necessary to attain
100% success rates ranged from 0.3 (moderate
infection) to six times the MIC (severe infection
or neutropenia). With the current state of knowl-
edge, and although further investigations are
necessary to refine a target Css/MIC value, it seems
reasonable to recommend a value of at least four
times the MIC.
P H A R M A C O L O G I C R E Q U I R E M E N T S
T O O P T I M I Z E T R E A T M E N T
B Y C O N T I N U O U S I N F U S I O N ?
Loading dose
The loading dose is used at the initiation of treat-
ment with a continuous infusion, mainly to enable
the attainment of an effective concentration, i.e.
between four and six times the MIC, from the first
minutes of therapy. This method is usually pre-
ferred for antibiotics with a long half-life or those
which bind strongly to proteins.
The question raised from the bacteriologic point
of view is whether, in the absence of a loading dose
and during continuous infusion, the interval
required to reach an effective plasma concentra-
tion might be sufficient to select mutant strains
with diminished sensitivity. Based on the MPC
concept, Negri and Baquero [22] defined this risk
for ceftazidime and cefepime versus E. cloacae
which was hyperproducing b-lactamases. The risk
was present from the beginning of the ceftazidime
infusion, but only from 6 h after the cefepime
infusion. An interval of about 45 min was neces-
sary to exceed the MPC. It is impossible to specify
whether this period was sufficient to allow the
appearance of mutant strains.
Based on these results, it is possible to conclude
that, if a loading dose is essential for ceftazidime, it
is probably less important in the case of cefepime,
but this view should nevertheless be reviewed
with regard to the bacteriologic documentation
and the window of selection, defined as the period
during which the concentration of the antibiotic is
higher than the MIC and lower than the MPC. It is
probable that the higher the MIC of strains and the
weaker the terrain of a non-neutropenic patient,
the more justification there is for using a loading
dose.
Monitoring for cefepime
It is indeed clearly stated in the Summarized
Product Characteristics that the cefepime dosage
must be adjusted to compensate for a lower rate of
renal excretion. Because it enables better control of
serum levels, the use of continuous infusion
should reduce the level of neurologic toxicity.
As for the other adverse events reported, their risk
of onset will probably not be affected, as they are
not related to the mode of product administration.
To date, no adverse event which was probably
attributable to cefepime has been reported in a
patient receiving the drug in a continuous infu-
sion. Cefepime may be assayed with the use of
chromatographic (HPLC) and microbiological
methods. However, because of the common use
of multiple drug therapies, HPLC seems to be the
most appropriate assay method.
The steady state for cefepime is attained 5 h
after the initiation of continuous infusion. It is
therefore not necessary to perform a plasma assay
before then. After 5 h, an estimation of the steady-
state concentration should allow evaluation of the
validity of the initial dosage administered. With
our current state of knowledge, the concentration
at the steady state should, in most clinical situa-
tions, be between four and six times the MIC, but
could reach ten to 50 times the MIC under certain
special circumstances (e.g. P. aeruginosa in cystic
fibrosis patients). In practice, a steady-state con-
centration of at least 15 mg/L, and close to 30 mg/
L, should meet the requirements in the majority of
situations.
Based on pharmacokinetic and pharmacody-
namic data, the daily dosage of 4 g is suited to
the most common clinical situations. The dosage of
6 g/day should be reserved for more difficult
situations, in the case of strains with reduced
sensitivity to cefepime, and in the context of indi-
vidual dosage adjustment.
C O N C L U S I O N
There is no absolute clinical proof of the super-
iority of continuous infusion over intermittent
administration; there are only isolated clinical
observations. The failure of antibiotic therapy in
the most severe infections (terrain or pathogens
implicated) does occur, and, in such patients,
the method of administration must be optimized,
to enable alignment of the pharmacokinetic/
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pharmacodynamic ratio and the mode of admin-
istration. In these areas, clinical studies will not
provide any answers, for methodological reasons.
There are numerous arguments in favor of con-
tinuous infusion: a better match with the pharma-
codynamic parameters of b-lactams, better control
of changes of levels in patients with unpredictable,
variable pharmacokinetic constants, the possibility
of treatment adjustment as a function of a defined
therapeutic target (plasma concentrations at the
steady state, Css/MIC ratio), ease of administra-
tion, and the prevention of overdose accidents.
Furthermore, continuous infusion may contribute
to reducing the risk of the emergence of resistant
mutants during treatment.
Several in vitro and experimental findings have
suggested that the therapeutic objective is to
achieve plasma concentrations at the steady state
which are four to six times the MIC of the incri-
minated microorganism. In the case of particular
strains with a high MIC (> 16 mg/L), this objec-
tive does not seem to be compatible with the
toxicologic risks of most b-lactams.
A bolus of the antibiotic prior to the initiation of
continuous infusion shortens the time needed to
obtain active concentrations in the plasma. For
cefepime, this loading dose should be 2 g in adults,
followed by the continuous infusion of 4 g/24 h.
The true value of the loading dose has not been
demonstrated, but it appears to be reasonable in
the most severely ill patients with a heavy infec-
tious load.
Pharmacologic therapeutic monitoring (plasma
assay at the steady state) is possible after about 5 h
of infusion, and enables subsequent adjustment of
the 24-h dosage as a function of the microorganism
identified and the MIC of the antibiotic, the objec-
tive being a minimum level of four to six times the
MIC value.
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